A practical guide for foreign applicants deciding whether invention patent filing, utility model filing, or a dual-track strategy makes more sense in China.
A practical answer for foreign brands and product teams deciding whether China trademark action should come before supplier conversations.
A practical guide to why a standard NDA is often not enough for China supplier conversations, and when contract protection needs to connect with trademark and patent timing.
A translation error in your PCT Chinese application can silently narrow the scope of your patent — sometimes permanently. Peter Lin explains how CNIPA handles correction requests, what the standard really is, and why prevention matters far more than remedy.
Many applicants entering China via PCT pay significantly more than they need to. Not because the fees are unavoidable — but because nobody walked them through the levers that exist. Peter Lin outlines a straightforward approach to reducing China patent costs without sacrificing meaningful protection.
Amending claims when you enter China's national phase via PCT sounds straightforward — but CNIPA applies strict "no new matter" rules that trip up many applicants. Peter Lin explains what's actually permitted, what gets rejected, and how to amend smartly.
On Reddit, people often ask: why do adult product (or “adult wellness”) patents get rejected so easily in China? As someone who’s been deep in the patent world for years, let me break it down.
When you enter China's national phase via PCT, a set of costs gets locked in based on decisions you made months or years earlier. Peter Lin explains what drives those costs — and how to structure your PCT application to avoid unnecessary expense before you even start prosecution.
Both the Paris Convention and PCT let you claim priority when filing in China — but the rules, deadlines, and strategic implications are very different. Peter Lin explains the one distinction that can make or break your China filing.
